

Effectiveness of peri-operative pregabalin as co-adjuvant analgesic for cosmetic liposuction

Submission date 07/02/2011	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 10/03/2011	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 10/03/2011	Condition category Surgery	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Luis Enrique Chaparro

Contact details
76 Stuart Street
Kingston General Hospital
Department of Anesthesia
Kingston
Canada
K7L2V7
+1 613 985 0424
luisdr74@yahoo.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title

Pregabalin as co-adjuvant analgesic for pain management after cosmetic liposuction: a randomised, double-blind and placebo-controlled clinical trial of effectiveness

Study objectives

Null hypothesis:

Adding pregabalin to a conventional analgesic scheme does not decrease the pain intensity with movement, analgesic request, opioid-related side effects (nausea, vomiting, somnolence) or time elapsed for returning to regular activities in patients undergoing cosmetic liposuction.

Alternate hypothesis:

Adding pregabalin to a conventional analgesic scheme decreases the pain intensity with movement, analgesic request, opioid-related side effects (nausea, vomiting, somnolence), or time elapsed for returning to regular activities in patients undergoing cosmetic liposuction.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Bioethics Committee of the IPS Universitaria (Universidad de Antioquia) (Comité de Bioética de la IPS Universitaria) (Universidad de Antioquia) approved on the 6th March 2006

Study design

Interventional randomised placebo-controlled double-blind parallel multicentre trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Post-operative pain

Interventions

Interventional arm:

Blinded capsules of pregabalin 75 mg. The patients started to take the medication the night before the surgery and continued the prescription twice daily (BID) up to the fourth day after surgery. They also had access to a prescription by the surgeon that included a weak opioid + acetaminophen and ibuprofen 200 mg as the circumstances arises (prn)

Control arm:

Blinded capsules of placebo (physically identical to pregabalin capsules). The patients started to take the placebos the night before the surgery and continued the prescription BID up to the fourth day after surgery. They also had access to a prescription by the surgeon that included a weak opioid + acetaminophen and ibuprofen 200 mg prn.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Pregabalin

Primary outcome measure

Numerical Rating Scale of Pain Intensity at rest and movement-induced at days 1, 2 3 and 4 after surgery

Secondary outcome measures

1. Post-operative (days 1, 2 3 and 4) morphine-equivalent request
2. Incidence of nausea, vomiting and sedation at the same time-points

Overall study start date

01/06/2006

Completion date

01/09/2007

Eligibility

Key inclusion criteria

1. Women aged 18 - 70 years
2. American Society of Anesthesiologists physical status score I - II
3. Scheduled for ambulatory cosmetic liposuction alone, liposuction and augmentation mammoplasty or liposuction and abdominoplasty under general anaesthesia

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Female

Target number of participants

Key exclusion criteria

1. Known allergy to any of the medications to be used (pregabalin, ibuprofen, tramadol or codeine)
2. Psychiatric illness
3. Chronic use (greater than 3 months) of steroids
4. Hypertension
5. Diabetes
6. Potential participants who were non-spanish speakers

Date of first enrolment

01/06/2006

Date of final enrolment

01/09/2007

Locations**Countries of recruitment**

Canada

Colombia

Study participating centre

76 Stuart Street

Kingston

Canada

K7L2V7

Sponsor information**Organisation**

IPS University (IPS Universitaria) (Colombia) - Surgical Ambulatory Unit

Sponsor details

Carrera 51A #62-42

Medellin

Colombia

-

+57(0) 4263 0171

ipsuniversitaria@ips.udea.edu.co

Sponsor type

University/education

Website

<http://ips.udea.edu.co/>

Funder(s)**Funder type**

University/education

Funder Name

IPS University (IPS Universitaria) (Colombia)- Surgical Ambulatory Unit, Department of Anaesthesia

Results and Publications**Publication and dissemination plan**

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration